

# PHASE 2 STROKE TRIAL PRESENTATIONS AT THE 2026 EUROPEAN STROKE ORGANISATION CONFERENCE

**Perth, Australia; 26 March, 2026** - Argenica Therapeutics Limited (ASX: AGN) (“Argenica” or the “Company”), a biotechnology company developing novel therapeutics to reduce brain tissue death after stroke and other acute neurological conditions, is pleased to announce the **acceptance of two abstracts for presentation** at the prestigious European Stroke Organisation Conference (ESOC), being held 6-8<sup>th</sup> May 2026 in Maastricht, Netherlands.

The first presentation is an oral presentation titled ***Final Results of the Phase II ARG-007-002 SEANCON trial of ARG-007 in Acute Ischaemic Stroke Patients Undergoing Endovascular Thrombectomy***. Professor Graeme Hankey, the Principal Investigator of the SEANCON study, is the presenting author.

The second presentation is a poster presentation titled ***Patients with Larger Infarct Cores Randomized to ARG-007 had Better Functional Outcomes: Results from the Phase II ARG-007-002 SEANCON Trial***. Dr Davide Carone, Senior Medical Director at Brainomix, is the presenting author.

The poster presentation has been selected as a **Best Poster Finalist**, which will be awarded at the conclusion of the conference.

All content to be presented at the conference will be embargoed until the time of the presentation.

**Dr Liz Dallimore, Managing Director of Argenica, commented:** *“ESOC is regarded as one of the top tier global stroke conferences, being selected for both an oral and poster presentation at ESOC is a strong indicator of the quality and impact of the Phase 2 SEANCON trial. Oral presentations are typically reserved for the highest-ranked abstracts, whilst being selected as a Best Poster Finalist is a notable distinction, reflecting that the study ranked among the top submissions in its category and was recognised for its scientific quality, originality, and potential impact by the conference reviewers. This is a fantastic recognition of the hard work and encouraging outcomes achieved in our Phase 2 trial of ARG-007 in acute ischaemic stroke patients.”*

*This announcement has been approved for release by the Managing Director of Argenica.*

For more information please contact: [info@argenica.com.au](mailto:info@argenica.com.au)

## **ABOUT ARGENICA**

Argenica Therapeutics Limited (ASX: AGN) is a clinical-stage biotechnology company developing innovative neuroprotective therapeutics to improve outcomes for patients following stroke and other acute neurological injuries. The Company's lead drug candidate, ARG-007, is designed to protect vulnerable brain tissue by reducing cell death and limiting secondary damage after an ischemic event. With a strong scientific foundation and a clear clinical development pathway, Argenica is focused on advancing novel treatments that have the potential to significantly improve patient recovery and transform the standard of care in acute neurology.